STAA 8.95 Staar Surgical Company $STAA Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2014 at 10:17 PM

STAA 8.95 Staar Surgical Company $STAA Hit a 52 week low of 8.75 Currently at 8.95 +0.07 +0.79% With a day low of 8.75 and a total volume of 230,300.

STAA Staar Surgical Company Recent Headline News

Commit To Purchase Staar Surgical At $7.50, Earn 17.4% Annualized Using Options
StockOptionsChannel.com - Fri Nov 07, 10:33AM CST
Investors considering a purchase of Staar Surgical Co. shares, but cautious about paying the going market price of $8.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
STAA: 8.95 (+0.07)

Shares of STAA Down 35.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 06, 11:00AM CST
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on July 7th, 2014 at $13.88. In approximately 4 months, STAAR Surgical has returned 35.16% as of today's recent price of $9.00.
STAA: 8.95 (+0.07)

STAAR Surgical To Present At The Stephens 2014 Fall Investment Conference
PR Newswire - Thu Nov 06, 6:00AM CST
STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that management will present at the Stephens 2014 Fall Investment Conference at the New York Palace Hotel on Tuesday, November 11 at 12:00 p.m. PT/3:00 p.m. ET.
STAA: 8.95 (+0.07)

Staar Surgical (STAA) Downgraded From Hold to Sell
at The Street - Wed Nov 05, 8:41AM CST
Staar Surgical STAA has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
STAA: 8.95 (+0.07)

Strong On High Volume: Staar Surgical (STAA)
at The Street - Tue Nov 04, 9:02AM CST
Trade-Ideas LLC identified Staar Surgical (STAA) as a strong on high relative volume candidate
STAA: 8.95 (+0.07)

STAAR Surgical Gains Final Step in Regulatory Approval for Visian® ICL(TM) with CentraFLOW® in China
PR Newswire - Tue Nov 04, 6:00AM CST
STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it has received the Approval Certification from CFDA to market its Visian ICL with CentraFLOW® technology in China effective November 3rd. The Visian ICL with CentraFLOW uses a proprietary port in the center of the ICL optic, KS-AquaPORT®, intended to optimize the flow of fluid within the eye without affecting the quality of vision. The CentraFLOW technology eliminates the need for surgeons to perform a YAG peripheral iridotomy procedure days before the ICL implant, simplifying the procedure and increasing patient comfort while providing the superior visual outcomes of the ICL.
STAA: 8.95 (+0.07)

Nasdaq stocks posting largest percentage decreases
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
ASMI: 41.20 (-0.20), TRMB: 27.31 (-0.17), STAA: 8.95 (+0.07), SCYX: 9.00 (+0.10), EPAY: 25.20 (+0.20), AEGR: 21.58 (-0.40)

Downgrade Alert for STAAR Surgical (STAA)
Comtex SmarTrend(R) - Fri Oct 31, 6:59AM CDT
STAAR Surgical (NASDAQ:STAA) was downgraded from Buy to Hold at Canaccord Genuity today. The stock closed yesterday at $11.04 on volume of 235,000 shares, above average daily volume of 199,000. Over the past year, STAAR Surgical has traded in a range of $9.98 to $19.74 and closed yesterday at $11.04, 11% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.9% while the 50-day MA has declined 0.5%.
STAA: 8.95 (+0.07)

Staar Surgical posts 3Q loss
Automated Insights - Thu Oct 30, 5:07PM CDT
MONROVIA, Calif. (AP) _ Staar Surgical Co. (STAA) on Thursday reported a loss of $2.7 million in its third quarter.
STAA: 8.95 (+0.07)

STAAR Surgical Reports Third Quarter Results
PR Newswire - Thu Oct 30, 3:01PM CDT
STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported revenue for the third quarter ended October 3, 2014 of $18.2 million, a 6.3% increase over $17.1 million reported for the third quarter of 2013. The results included quarterly sales of $10.6 million of the Company's Visian ICL product portfolio, $5.8 million of its IOL products and $1.8 million of its lower margin Other Product sales. The effect of foreign currency exchange reduced sales by $0.4 million during the quarter. On a constant currency basis, revenues grew 9% during the third quarter of 2014 compared to the third quarter of 2013.
STAA: 8.95 (+0.07)

Downtrend Call Working As STAAR Surgical Stock Falls 21.3% (STAA)
Comtex SmarTrend(R) - Thu Oct 30, 9:50AM CDT
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on July 7th, 2014 at $13.88. In approximately 4 months, STAAR Surgical has returned 21.25% as of today's recent price of $10.93.
STAA: 8.95 (+0.07)

STAAR Surgical Has Returned 26.4% Since SmarTrend Recommendation (STAA)
Comtex SmarTrend(R) - Thu Oct 23, 9:13AM CDT
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on July 7th, 2014 at $13.88. In approximately 4 months, STAAR Surgical has returned 26.40% as of today's recent price of $10.22.
STAA: 8.95 (+0.07)

STAAR Surgical Announces Third Quarter 2014 Results Release Date, Conference Call And Webcast
PR Newswire - Thu Oct 23, 6:00AM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it will release its financial results for the third quarter ended October 3, 2014 on Thursday, October 30, 2014 after the market close.
STAA: 8.95 (+0.07)

STAAR Surgical to Webcast Investor Presentations at American Academy of Ophthalmology's Annual Meeting
PR Newswire - Fri Oct 17, 6:00AM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that the Company will webcast its presentation at an Investor Breakfast Meeting on Saturday, October 18, 7:00 a.m. CT at the American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, IL.
STAA: 8.95 (+0.07)

Shares of STAA Down 17.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 15, 5:35PM CDT
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on July 7th, 2014 at $13.88. In approximately 3 months, STAAR Surgical has returned 17.15% as of today's recent price of $11.50.
STAA: 8.95 (+0.07)

STAAR Surgical Has Returned 18.0% Since SmarTrend Recommendation (STAA)
Comtex SmarTrend(R) - Wed Oct 08, 4:59PM CDT
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on July 7th, 2014 at $13.88. In approximately 3 months, STAAR Surgical has returned 18.01% as of today's recent price of $11.38.
STAA: 8.95 (+0.07)

STAAR Surgical CEO Barry G. Caldwell to step down in March 2015
M2 - Mon Oct 06, 7:27AM CDT
Implantable lenses company STAAR Surgical Company (NasdaqGM:STAA) reported on Sunday the planned retirement of its president & CEO Barry G. Caldwell on 1 March 2015.
STAA: 8.95 (+0.07)

STAAR Surgical CEO to Retire in March 2015
PR Newswire - Fri Oct 03, 3:15PM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that Barry G. Caldwell, President & CEO (64), will retire on March 1, 2015. The Board of Directors has initiated a search to identify Mr. Caldwell's replacement. Mr. Caldwell will continue to lead the Company, serve on the Board of Directors and assist in the leadership transition process. In addition, effective with this retirement, Mr. Caldwell will become a consultant to STAAR through March 1, 2016.
STAA: 8.95 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

EQT Acquires Range Resources: Redefining Gas Markets

A New Chapter in Natural Gas Who would have thought? EQT Corporation, that sturdy old veteran in the natural gas game, finally made its move and snatched up Range Resources, sprinting right out of left field. This merger isn't just about two companies shaking hands; it's about rewriting the entire narrative of America's natural gas landscape. With this acquisition, EQT's...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Minesto Teams Up to Unlock Tidal Power in Maldives

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...